1. Academic Validation
  2. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimetics

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimetics

  • J Med Chem. 1999 Apr 8;42(7):1203-12. doi: 10.1021/jm980537b.
P S Dragovich 1 T J Prins R Zhou S A Fuhrman A K Patick D A Matthews C E Ford J W Meador 3rd R A Ferre S T Worland
Affiliations

Affiliation

  • 1 Agouron Pharmaceuticals, Inc., 3565 General Atomics Court, San Diego, California 92121, USA.
Abstract

The structure-based design, chemical synthesis, and biological evaluation of various ketomethylene-containing human rhinovirus (HRV) 3C protease (3CP) inhibitors are described. These compounds are comprised of a peptidomimetic binding determinant and an ethyl propenoate Michael acceptor moiety which forms an irreversible covalent adduct with the active site cysteine residue of the 3C Enzyme. The ketomethylene-containing inhibitors typically display slightly reduced 3CP inhibition activity relative to the corresponding peptide-derived molecules, but they also exhibit significantly improved Antiviral properties. Optimization of the ketomethylene-containing compounds is shown to provide several highly active 3C Protease Inhibitors which function as potent antirhinoviral agents (EC90 = <1 microM) against multiple virus serotypes in Cell Culture.

Figures
Products